BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/23/2021 6:56:55 AM | Browse: 586 | Download: 2005
Publication Name World Journal of Nephrology
Manuscript ID 67983
Country Thailand
ISSN 2220-6124 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, Research & Experimental
Manuscript Type Prospective Study
Article Title Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis
Manuscript Source Unsolicited Manuscript
All Author List Piyatida Chuengsaman, Surapong Narenpitak and Suchai Sritippayawan
Funding Agency and Grant Number
Corresponding Author Piyatida Chuengsaman, MD, Doctor, Doctor, Banphaeo Dialysis Group, Banphaeo Hospital (Public Organization), 198 Moo 1 Banphaeo, Banphaeo 74120, Samutsakhon, Thailand. pchuengsaman@gmail.com
Key Words Recombinant human erythropoietin; Anemia; Peritoneal dialysis; Chronic kidney disease; Epoetin alfa
Core Tip This was an open-label, single-arm, prospective, multicenter study of Hema-Plus®, a recombinant human erythropoietin (rHuEPO) for management of anemia in 30 Thai chronic kidney disease patients who started peritoneal dialysis with hemoglobin (Hb) lower than 9.5 g/dL and who had not previously received epoetin. The results showed that the rHuEPO could significantly increase Hb from baseline throughout the 12-wk treatment duration with acceptable safety profile. The quality of life (QoL) scores at week 12 assessed using KDQOL-36 were significantly increased from baseline in all domains.
Publish Date 2021-11-23 06:30
Citation Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121
URL https://www.wjgnet.com/2220-6124/full/v10/i6/109.htm
DOI https://dx.doi.org/10.5527/wjn.v10.i6.109
Full Article (PDF) WJN-10-109.pdf
Full Article (Word) WJN-10-109.docx